
Overview
Genomtec is the creator of Genomtec ID, a mobile platform for genetic diagnostics at the point of patient care. The company has developed the GenomtecID Respiratory Panel 5-Plex (RP5-PLEX), which detects viruses and bacteria causing respiratory tract infections and is the only solution of its kind in Europe. Additionally, Genomtec is preparing for technology trials in Asia related to its diagnostic devices.
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2025, 23 days late). All were audited by a statutory auditor.
- 202507/08/2026
- 202414/07/2025
- 202311/07/2024
- 202229/06/2023
- 202101/07/2022
- 202014/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 2.60
- High
- PLN 2.66
- Low
- PLN 2.55
- Volume
- 6.6K
- Avg. vol.
- 35.71K
- Market cap
- PLN 44.37M
- P/E ratio
- –
- EPS
- -PLN 0.67
- Shares outstanding
- 17.06M
- 52-week
- PLN 2.35 – 2.93
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLGNMTC00017
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 2.97k | USD -546.19k | USD -559.43k |
| Q1 2026 | USD 4.32k | USD -578.61k | USD -593.19k |
| Q4 2025 | USD 1.26k | USD -777.75k | USD -804.87k |
| Q1 2025 | – | – | – |
Results for Q3 2026:Nov 30, 2026
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

Miron Tokarski to speak at the upcoming webinar „Meeting the Challenges and Unlocking the Potential of Point-of-Care Molecular Diagnostics”

Another patent granted. Another step in building global protection of Genomtec's molecular diagnostics technology

Genomtec secures PLN 11 million from share issue to finalize its global M&A strategy and commercialize breakthrough Genomtec ID and OncoSNAAT® technologies

Launch of public offering of Genomtec shares to raise funds for completing the M&A process and commercializing Genomtec ID and OncoSNAAT® technologies

Genomtec plans a share issue. Proceeds will support the M&A process and commercialization of projects. The company has signed an investment agreement with a key shareholder.

As part of the M&A process, Genomtec prepares to test its technology with potential partners in Asia
Industry
Offer
- Diagnostic equipment
- RT-LAMP diagnostic kits
- Molecular diagnostic tests
Websites
The site is available in: Polish and English. The site targets these markets: United States.
- genomtec.comStrona główna - GenomtecWordPress 6.9Yoast SEOWWPMLApache
Job offers
The company lists many job openings on its own careers page: genomtec.com/o-nas. The first ones are below.
Authorized Representatives
Manner of representation
The company is represented by each member of the management board independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
GMT Genomics S.A. | 297,136.68 USD | 100% | ||
GMT Id S.A. | 162,074.55 USD | 100% |
Capital group
| Name | Ownership |
|---|---|
OPIS GRUPY KAPITAŁOWEJ GENOMTEC S.A. | 10% |
Bank accounts
Registered as a VAT taxpayer on 2016-12-28.
49 1090 2398 0000 0001 3577 0279
58 1090 2398 0000 0001 4187 6849
32 1090 2398 0000 0001 4700 7550
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
9 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Feb 26, 2021 | Transformation registered | |
| Feb 11, 2021 | Transformation registered | |
| Jan 19, 2021 | Shareholders' meeting convened | |
| Jan 19, 2021 | Transformation registered | |
| Oct 15, 2020 | Transformation registered |
Public aid
18 public aid cases recorded, with a total value of $10,391,382.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 20, 2023 | Aid for research and development projects: experimental development | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Dec 20, 2023 | Aid for research and development projects: industrial research | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Dec 20, 2023 | Aid for SMEs for innovation support | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
3 projects recorded: 2 from FE lists ($119,285) and 1 Commission grant (FTS) ($55,960).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2022-02-01 | Support for preparing an application for an Eurogrant under the EIC Accelerator programme | $14,356$14,356 | Operational Programme Smart Growth | |
| 2019-11-01 | Microrna-based tool for non-invasive early-stage cancer diagnosis | $55,960$55,960 | 1.1.31 - Horizon 2020 | |
| 2017-12-01 | Obtaining international patent protection for an invention concerning an innovative method for detecting genetic material in a biological sample and a mobile diagnostic device for implementing it. | $104.9K$104,929 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Replicon sp. z o.o. | $50,379.75 | replicon.pl | ||
| Amplicon sp. z o.o. | $48,330.99 | amplicon.pl | ||
| Grupa Psychotronics sp. z o.o. | $27,307.51 | psychotronics.pl | ||
| NLA Systems sp. z o.o. | $24,304.69 | nla-systems.com | ||
| Spectra-Laser sp. z o.o. | $19,563.74 | spectra-laser.pl | ||
| V-Lab sp. z o.o. | $16,594.61 | vlab.com.pl | ||
| Nucleotica sp. z o.o. | $5,315.32 | nucleotica.com | ||
| Labomatica sp. z o.o. | $3,452.74 | labomatica.com | ||
| Kamika sp. z o.o. | $1,076.72 | kamika.pl | ||
| Bioaccure sp. z o.o. | $1,109.95 | bioaccure.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-06-11 | Share capital increase (1,506,463.40 PLN → 1,706,463.40 PLN) | |
| 2025-09-16 | Share capital increase (1,486,712.60 PLN → 1,506,463.40 PLN) | |
| 2025-03-19 | Share capital increase (1,332,457.00 PLN → 1,486,712.60 PLN) | |
| 2024-05-16 | Share capital increase (1,225,788.60 PLN → 1,332,457.00 PLN) | |
| 2023-10-06 | Share capital increase (1,179,554.00 PLN → 1,225,788.60 PLN) |
FAQ
Last updated: 2026-10-08